Islet Transplantation Overview

Principles

Definition

Islet transplantation is a therapeutic modality and significant area of biomedical research involving the surgical or percutaneous infusion of isolated pancreatic islets, with the primary objective of restoring endogenous insulin secretion in patients with diabetes, particularly type 1 diabetes mellitus. Research within this domain encompasses the development and optimization of techniques for islet isolation, purification, and delivery, strategies to mitigate immune rejection and enhance graft survival, and the comprehensive evaluation of long-term physiological function and associated complications of transplanted islets. Its academic and clinical significance resides in its potential to achieve insulin independence and optimize glycemic control, thereby ameliorating the debilitating chronic sequelae of diabetes.

Ontological type

Immunosuppression Strategies

Islet Isolation Methods

Graft Survival and Function

Key developments

Key Figures

Immunologic Foundations era

Paul E. Lacy [1] was a leading figure in the Immunologic Foundations era, with affiliations at Washington University in St. Louis [3] and San Raffaele University of Rome [4]. His work on transplantation site effects in pancreatic islet isografts in diabetic rats [7] and on transplantation of isolated pancreatic islets into the portal vein [9] advanced understanding of engraftment sites and delivery methods, while the anti-dendritic cell antibody pretreatment study [8] highlighted immunomodulatory strategies to prevent rejection, collectively shaping early immunologic approaches in islet transplantation. David E.R. Sutherland [2] had affiliations with Harvard University [5] and Stanford University [6] during this era. His studies quantified the rate of regression of glomerular lesions after pancreatic islet transplantation [10], explored the differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection [11], and reported on the effects of pancreatic islet transplantation on glomerular lesions in experimental diabetes [12].

Clinical Protocol Standardization era

Gregory S. Korbutt [1], affiliated with the University of Alberta [3], helped anchor the clinical emergence of islet transplantation during the era of protocol-driven standardization. His work on Successful Islet Transplantation [4] demonstrated that clinical islet transplantation could achieve meaningful outcomes in humans, a cornerstone for multicenter adoption and protocol standardization; and the Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways [5] advanced immunomodulatory approaches to extend graft survival, informing safety measures and donor-source expansion during this era. Ray V. Rajotte [2], affiliated with the University of Alberta [3], contributed to defining islet transplantation within this era's framework of standardized immunosuppression and safety protocols. In Successful Islet Transplantation [4], his collaboration helped demonstrate translational potential and reinforced the need for costimulation-modulating strategies; and in Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways [5], his work highlighted how targeted immune modulation could reduce early graft loss and broaden donor sources, a core concern of Edmonton-inspired protocols.

Engineered Immunomodulated Niches era

Mark A. Atkinson [1] is a key figure in islet biology during this era, with affiliations at University of Massachusetts Chan Medical School [3] and Emory University [4]. His contributions are exemplified by the 2012 paper 'Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients' [7], which demonstrated autoreactive CD8 T cell involvement in insulitic lesions and underscored the importance of targeted immunomodulation to prevent early inflammation in islet implants. Bart O. Roep [2] has been a prominent contributor in this era, with affiliations at Baylor College of Medicine [5] and Radboud University Nijmegen [6]. His contributions through the same 2012 paper [7] highlighted autoreactive CD8 T cell involvement in insulitic lesions, informing design principles for immunomodulated niches that aim to decouple systemic immunosuppression from islet survival and support revascularization within engineered implants.